<DOC>
	<DOCNO>NCT01603979</DOCNO>
	<brief_summary>This Phase 1 , multi-center , open-label , multiple dose , dose escalation study evaluate safety , tolerability , dose limit toxicity ( DLTs ) , maximum tolerate dose ( MTD ) and/or Recommended Phase 2 Dose ( RP2D ) , pharmacokinetic ( PK ) , pharmacodynamics , preliminary anti-tumor activity AV-203 , ERBB3 inhibitory antibody , administer every 2 week via intravenous ( IV ) infusion subject metastatic advance solid tumor . Once RP2D determine , patient tumor types interest evaluate expansion cohort RP2D safety anti-tumor activity .</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Study AV-203 , ERBB3 Inhibitory Antibody , Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>â‰¥ 18 year age Histologically and/or cytologically confirm primary diagnosis Metastatic advance solid tumor , recur progress follow standard therapy , standard therapy exist Must available tumor tissue willing undergo biopsy prior enrollment Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 Blood Chemistry Hematology result within defined limit History severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational agent Current central nervous system ( CNS ) leptomeningeal metastasis , history CNS leptomeningeal metastasis . Significant conduction disturbance , history severe arrhythmia , history familial arrhythmia Significant cardiovascular disease Significant thromboembolic vascular disorder within prior 3 month Any medical condition psychiatric condition , opinion Investigator , might interfere subject 's participation trial interfere interpretation trial result Known history positive result hepatitis C , hepatitis B , human immunodeficiency virus . For female subject , pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>AV203</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>ERBB3</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>HER3</keyword>
</DOC>